On October 5, 2022 Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, reported that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2022 (Press release, Lytix Biopharma, OCT 5, 2022, View Source [SID1234621749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be released on the SITC (Free SITC Whitepaper) website 7 November 14:00 CEST. The poster is scheduled for presentation during the SITC (Free SITC Whitepaper) meeting 8-12th November 2022.

Poster Details:

Abstract Title: Molecular mechanisms of DC activation by melanoma cells responding to LTX-315.

Presenter: Takahiro Yamazaki, Department of Radiation Oncology, Weill Cornell Medical College, New York, USA

About SITC (Free SITC Whitepaper)

The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual meeting provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.